Supplementary Figures 1-10. from Systematic <i>In Vivo</i> Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma

Abstract

&lt;p&gt;Supplementary Figure 1: Locations and types of chromatin regulator mutations found in human lung adenocarcinomas. Supplementary Figure 2: Identification of high efficiency Brg1, Arid1a and Setd2 sgRNAs using a fluorescent reporter-based sensor assay. Supplementary Figure 3: Examples of tumors with mixed expression of Brg1, Arid1a and H3K36me3. Supplementary Figure 4: Proliferative and apoptotic rates of KrasG12D/+ tumors targeted with sgRNAs against GFP, Brg1, Arid1a, or Setd2. Supplementary Figure 5: Identification of chromatin regulator expression status and measurement of tumor cell purity in RNA-Seq samples. Supplementary Figure 6: Ingenuity Pathway Analysis of top 10 enriched canonical pathways in Arid1a and Setd2 deficient tumors. Supplementary Figure 7: Proliferative and apoptotic rates of KrasG12D/+;p53-/- tumors targeted with sgRNAs against GFP, Brg1, Arid1a, or Setd2. Supplementary Figure 8: Analysis of markers of tumor cell identity in early and late KrasG12D/+;p53-/- tumors. Supplementary Figure 9: Representative images of tumors from KrasG12D/+;p53flox/flox mice, and the distinct morphology of Setd2 deficient tumors. Supplementary Figure 10: Analysis of multinucleate giant cells, aberrant mitoses and DNA damage in Setd2 deficient tumors.&lt;/p&gt;